SCHEMBL1890830

SCHEMBL1890830

COC(=O)c1nn(CCNC(=O)OC(C)(C)C)c(C(=O)OC)c1[N+](=O)[O-]

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.37
GFER P55789 1/20 0.37
DRD2 P14416 3/20 0.36
BRD4 O60885 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
MEN1 O00255 5/20 0.34
KMT2A Q03164 5/20 0.34
CA12 O43570 2/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA9 Q16790 2/20 0.34
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
PKM P14618 1/20 0.34
GAA P10253 1/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31616888 0.89 ALDH1A1 (0.35) ALDH1A1GFERDRD2BRD4SMN1; SMN2
SCHEMBL1007078 0.86 ALDH1A1 (0.37) ALDH1A1GFERDRD2BRD4TDP1
SCHEMBL29544458 0.80 GAA (0.40) ALDH1A1GFERDRD2BRD4SMN1; SMN2
SCHEMBL8296901 0.78 KMT2A (0.42) ALDH1A1SMN1; SMN2MEN1KMT2ACNR1
SCHEMBL1079551 0.78 GAA (0.50) ALDH1A1SMN1; SMN2TDP1GAALMNA
SCHEMBL5163133 0.77 ALDH1A1 (0.38) ALDH1A1GFERDRD2BRD4SMN1; SMN2
SCHEMBL20399777 0.76 BRD4 (0.41) ALDH1A1GFERDRD2BRD4MEN1
SCHEMBL18665224 0.76 CA12 (0.43) ALDH1A1GFERDRD2BRD4TDP1
SCHEMBL8253700 0.75 MEN1 (0.42) ALDH1A1SMN1; SMN2MEN1KMT2ACNR1
SCHEMBL27244243 0.74 SMN1; SMN2 (0.37) ALDH1A1SMN1; SMN2MEN1KMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118236-A1 HETEROCYCLIC COMPOUND GRIN1, GRM1, GRIK1 ALDH1A1 614/4885GFER 1046/4885DRD2 510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.